https://www.selleckchem.com/pr....oducts/Fulvestrant.h
Compared with non-cationic amphiphilic antihistamine users, patients who received cationic amphiphilic antihistamines had a significantly longer median overall survival (24.8 versus10.4 months; Log-rank, p=0.018) and progression-free survival (10.6 versus4.93 months; Log-rank, p=0.004). The use of cationic amphiphilic antihistamines was associated with an approximately 50% lower risk of all-cause mortality (HR, 0.55 [95% CI 0.34-0.91]). Survival benefits were not seen in patients who received cationic amphiphilic antihistamines befo
Like
Comment
Share
